Iain McGill, Quell Therapeutics CEO

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

As­traZeneca is part­ner­ing with Quell Ther­a­peu­tics to de­vel­op reg­u­la­to­ry T cell ther­a­pies for type 1 di­a­betes and in­flam­ma­to­ry bow­el dis­ease, join­ing the grow­ing move­ment of com­pa­nies and aca­d­e­m­ic groups de­vel­op­ing cell ther­a­pies for au­toim­mune dis­eases.

As­traZeneca will pay Quell, a Lon­don-based biotech, $85 mil­lion up­front, with a po­ten­tial $2 bil­lion on the line in down­stream mile­stones, plus roy­al­ties. The duo will work to­geth­er on de­vel­op­ing two reg­u­la­to­ry T cell ther­a­pies (or Treg ther­a­pies), both of which are still pre­clin­i­cal. Quell is in charge of man­u­fac­tur­ing the ther­a­pies un­til the end of the first clin­i­cal tri­als, af­ter which As­traZeneca has the op­tion to li­cense, de­vel­op and com­mer­cial­ize the treat­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.